Review decision – July 2019
Decision to update and re-issue the guidance
We would like to update you on the decision made regarding the review of the existing guidance on TA464; Bisphosphonates for treating osteoporosis.
We had proposed that the recommendation in TA464 should be updated and re-issued without going through the full technology appraisal process.
NICE was proposing to update and re-issue the guidance in light of concerns raised by the MHRA that the existing recommendations were being misinterpreted.
After consideration of all the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.
Consequently, the recommendations in TA464 have be amended and the guidance has been re-issued. The re-issued guidance no longer includes a risk score emphasises the need to apply clinical judgement in considering when treatment should be started.
This page was last updated: